| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Non-cleavable Linker for ADC synthesis
|
|---|---|
| ln Vitro |
ADC cytotoxins are connected to antibodies through an ADC connector to form ADCs [1].
|
| References | |
| Additional Infomation |
Crosslinking reagents
Crosslinking reagents typically have two reactive groups, located at opposite ends of a molecule, capable of reacting with the side chains of amino acids in proteins to form bridges between them; this allows for the determination of the location of native reactive regions in proteins; they can also be used for other macromolecules, such as glycoproteins, nucleic acids, or other substances. Antibody-drug conjugates (ADCs) are among the fastest-growing drugs in the field of cancer treatment. After half a century of research, the approvals of brentuximab vedotin (2011) and trastuzumab emtansine (2013) paved the way for ongoing clinical trials evaluating more than 60 other ADC candidates. The limited success of first-generation antibody-drug conjugates (ADCs, developed in the early 21st century) prompted strategies to bring second-generation ADCs to market. Second-generation ADCs offer higher levels of cytotoxic drug conjugation, lower levels of naked antibodies, and more stable drug-antibody linkers. Furthermore, lessons learned over the past decade are being applied to the development of third-generation ADCs. In this review, we will discuss how to select the best target antigen and appropriate cytotoxic drugs; how to design optimized linkers; how to discover bioorthogonal coupling chemistry; and toxicity issues. Selecting and modifying antibodies for site-specific drug conjugation to improve homogeneity and stability, as well as exploring new conjugation chemistry and mechanisms of action, are the focus of ADC research. [1] |
| Molecular Formula |
C16H20N2O14S2
|
|---|---|
| Molecular Weight |
528.4650
|
| Exact Mass |
550.017
|
| Elemental Analysis |
C, 36.37; H, 3.81; N, 5.30; O, 42.38; S, 12.13
|
| CAS # |
82436-77-9
|
| Related CAS # |
BS3 Crosslinker disodium;127634-19-9
|
| PubChem CID |
123854
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
>300°C
|
| LogP |
-1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
34
|
| Complexity |
1010
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
VYLDEYYOISNGST-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H20N2O14S2/c19-11-7-9(33(25,26)27)15(23)17(11)31-13(21)5-3-1-2-4-6-14(22)32-18-12(20)8-10(16(18)24)34(28,29)30/h9-10H,1-8H2,(H,25,26,27)(H,28,29,30)
|
| Chemical Name |
1-[8-(2,5-dioxo-3-sulfopyrrolidin-1-yl)oxy-8-oxooctanoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid
|
| Synonyms |
82436-77-9; bis(sulfosuccinimidyl)suberate; BS3 Crosslinker; BSSIS; bis(sulphosuccinimidyl)suberate; bis(sulfosuccinimidyl) suberate; Disulfosuccinimidyl suberate; BS(3) Cpd;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8923 mL | 9.4613 mL | 18.9226 mL | |
| 5 mM | 0.3785 mL | 1.8923 mL | 3.7845 mL | |
| 10 mM | 0.1892 mL | 0.9461 mL | 1.8923 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
